TheraRadar
Clinical-Stage Companies / Navidea Biopharmaceuticals

Navidea Biopharmaceuticals

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 3/2/2022

17
Total Trials
6
Phase 3
6
Phase 2
0
Recruiting
156
Score

Pipeline by Phase

Phase 3
6
Phase 2
6
Phase 1
6

Therapeutic Focus

Rheumatoid Arthritis Arthritis, Rheumatoid Parkinson's Syndrome Breast Cancer Melanoma

Clinical Trials (17)

NCT05246280 Phase 3 TERMINATED

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Started: 3/2/2022

NCT01950455 Phase 3 TERMINATED

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Started: 11/1/2013

NCT01950468 Phase 3 WITHDRAWN

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Started: 4/1/2017

NCT00911326 Phase 3 TERMINATED

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Started: 5/1/2009

NCT00671918 Phase 3 COMPLETED

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

Started: 4/1/2008

NCT01106040 Phase 3 COMPLETED

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Started: 6/1/2010

NCT04947137 Phase 2 COMPLETED

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

Started: 5/27/2021

NCT04078191 Phase 2 TERMINATED

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

Started: 9/14/2021

NCT01812213 Phase 2 TERMINATED

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

Started: 3/1/2013

NCT03938636 Phase 2 COMPLETED

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

Started: 4/8/2019

NCT02201420 Phase 2 COMPLETED

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

Started: 9/1/2014

NCT03157167 Phase 1 COMPLETED

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

Started: 12/1/2017

NCT03332940 Phase 1 TERMINATED

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Started: 12/6/2017

NCT02865434 Phase 1 COMPLETED

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Started: 1/1/2017

NCT03029988 Phase 1 TERMINATED

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

Started: 7/26/2017

NCT02683421 Phase 1 COMPLETED

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

Started: 7/1/2016

NCT03241446 Phase 1 WITHDRAWN

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

Started: 9/1/2017

Drug Candidates

Tc99m-tilmanocept TC99m-tilmanocept Tc99m tilmanocept Tc 99m tilmanocept Tc 99M Sulfur Colloid [18F]NAV4694 Tilmanocept (Technetium Tc 99m tilmanocept Injection) Tilmanocept NAV5001 DaTscan
Activity Status: Stale
Last Trial Started: 3/2/2022
Last Trial Ended: 7/9/2024
Trials (12 months): 0
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.